4 results
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
Efficacy of BEZ235 on objective response rate according to RECIST 1.1
To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.
PrimaryImproved woundhealing in 30 days in patients with an open revascularisation of the lower extremities after treatment with 4 dosages of 2 grams ascorbic acid on 4 consecutive days. (First dosage 1 hour preoperative)SecondaryWith preoperative…